Side-by-side · Research reference

CardiogenvsCartalax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BAnimal-MechanisticHUMAN-REVIEWED10/32 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

01Mechanism of Action

Parameter

Cardiogen

Cartalax

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

Cartalax

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

—

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

—

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Animal mechanistic studies only

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

—

Animal model dose

—

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

Human dosing

—

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

03Metabolic / Fat Loss Evidence

Parameter

Cardiogen

Cartalax

Fat loss evidence

—

None — primary target is cartilage and bone tissue, not adipose

04Side Effects & Safety

Parameter

Cardiogen

Cartalax

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Documented adverse effects

—

None reported in indexed animal studies

Human safety data

—

Not available in PubMed-indexed literature

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

Cartalax

·Unknown due to lack of human clinical trial data

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

05Administration Protocol

Parameter

Cardiogen

Cartalax

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

3. Timing

Variable — often evening injection. No established circadian preference.

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

—

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

—

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

Cartalax

— no documented stacks